Aging & Longevity

Late-onset and functional hypogonadism in aging men: an integrated perspective on hormonal, sleep, and metabolic dimensions.

TL;DR

An integrated perspective on male reproductive aging that incorporates hormonal, metabolic, and sleep-related dimensions supports earlier diagnosis and personalized therapeutic strategies, with implications for improving men's health, quality of life, and longevity.

Key Findings

Progressive testosterone decline in aging men interacts with circadian disruption, sleep disorders, and metabolic imbalance in a bidirectional and clinically relevant manner.

  • The interaction between testosterone decline and sleep/metabolic dysfunction is described as bidirectional, meaning each dimension can worsen the others.
  • The review synthesized current literature on hormonal decline, sleep disturbances, and metabolic dysfunction in aging men.
  • The authors characterize this as a 'multifaceted' process not fully captured by existing terminology such as 'andropause' or late-onset hypogonadism (LOH).

Male hormonal decline is subtle and frequently underdiagnosed, unlike the abrupt hormonal changes seen in women.

  • The gradual nature of male reproductive aging is contrasted explicitly with the more abrupt hormonal changes in women (menopause).
  • The subtle progression is identified as a key reason for underdiagnosis and delayed intervention.
  • Associated clinical manifestations include reduced libido, fatigue, muscle loss, mood disturbances, and visceral adiposity.

Sleep disturbances act both as consequences and amplifiers of endocrine and metabolic dysfunction in aging men.

  • Specific sleep disorders identified include insomnia, sleep fragmentation, and obstructive sleep apnea (OSA).
  • The relationship between sleep disturbances and hormonal/metabolic dysfunction is described as bidirectional.
  • Sleep disorders are positioned as both outcomes of hormonal decline and contributors to further endocrine and metabolic deterioration.

Current diagnostic criteria for late-onset hypogonadism (LOH) remain debated, limiting clinical recognition and delaying interventions.

  • The terms 'late-onset hypogonadism' and 'andropause' are described as 'controversial and insufficient to capture the multifaceted nature of this process.'
  • Lack of consensus on diagnostic criteria is identified as a barrier to timely clinical recognition.
  • The controversy around terminology and criteria is presented as a clinically meaningful problem affecting patient care.

The distinction between late-onset hypogonadism (LOH) and functional hypogonadism is clinically meaningful because functional hypogonadism may be partially reversible.

  • Functional hypogonadism, unlike LOH, is characterized as potentially reversible.
  • Identified reversibility strategies include weight reduction, metabolic optimization, physical activity, and sleep-focused interventions.
  • This distinction has direct implications for clinical management and the selection of appropriate therapeutic strategies.

An integrated management approach addressing hormonal, metabolic, and sleep-related dimensions is recommended for aging men with hypogonadism.

  • The review advocates for 'personalized therapeutic strategies' based on the integrated perspective.
  • Earlier diagnosis is identified as a key clinical implication of adopting this integrated framework.
  • The stated goals of this approach include improving men's health, quality of life, and longevity.
  • The review is narrative in nature, which the authors acknowledge 'may restrict systematic generalization of findings.'

What This Means

This research suggests that the hormonal changes men experience as they age — often called 'andropause' or late-onset hypogonadism — are far more complex than a simple drop in testosterone. The review highlights that declining testosterone, poor sleep, and metabolic problems like obesity and insulin resistance all feed into each other in a cycle that worsens each condition. Sleep disorders such as sleep apnea and insomnia, for example, can both result from low testosterone and make testosterone levels fall even further. Unlike menopause in women, this process in men is gradual and easy to miss, which means many men go undiagnosed and untreated for years. The review also draws an important distinction between two types of low testosterone in older men. 'Late-onset hypogonadism' refers to a true age-related hormonal decline, while 'functional hypogonadism' is low testosterone caused by reversible factors like excess body weight, poor sleep, or metabolic disease. This matters because functional hypogonadism may improve — without hormone therapy — through lifestyle changes such as losing weight, exercising, and treating sleep disorders. The authors argue that current medical definitions and diagnostic criteria are not clear enough to reliably tell these two conditions apart, which delays appropriate treatment. This research suggests that doctors and patients would benefit from thinking about male reproductive aging as an interconnected problem involving hormones, metabolism, and sleep all at once, rather than focusing on any one factor in isolation. A more holistic approach could lead to earlier detection, more targeted treatments, and better overall health outcomes for aging men. Because this is a narrative review rather than a clinical trial, it summarizes and interprets existing evidence rather than generating new data, so its conclusions reflect the authors' synthesis of the field.

Have a question about this study?

Citation

M. L. Andersen, J. M. Sanches, T. Alvarenga, M. Toricelli, M. Vasco, S. Tufik. (2026). Late-onset and functional hypogonadism in aging men: an integrated perspective on hormonal, sleep, and metabolic dimensions.. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-026-02981-6